Wet AMD is a leading cause of central vision loss in older adults, resulting from abnormal blood vessel formation beneath the retina’s macula. VEGF plays a central role in this process, promoting fragile vessels that leak fluid and blood. Without treatment, these changes can rapidly damage vision. Allergan Anti-VEGF therapy has become a cornerstone of modern management, improving outcomes and reducing disease progression.

Disease Mechanism and Symptoms

The central macula is essential for activities like reading and recognizing faces. In wet AMD, VEGF stimulates neovascularization, which leads to swelling and tissue damage. Early symptoms include blurred vision, distortion of straight lines, and blind spots. Prompt medical attention is critical, as early therapy can prevent irreversible damage.

Allergan Anti-VEGF Treatments

Allergan’s anti-VEGF drugs inhibit VEGF, preventing abnormal vessel growth and leakage. This slows disease progression and can restore some lost vision. Abicipar Pegol, developed with Molecular Partners, is designed for longer intervals between injections, reducing treatment burden while maintaining effectiveness.

Standard Care and Monitoring

Alongside Allergan’s drugs, therapies like ranibizumab, aflibercept, and bevacizumab remain widely used. Treatment involves intravitreal injections every few weeks, with ophthalmologists monitoring response via retinal imaging. New technologies, such as sustained-release implants, are being developed to further ease treatment schedules.

Maintaining Eye Health

Patients benefit from combining anti-VEGF therapy with healthy lifestyle choices. Avoiding smoking, maintaining cardiovascular health, and consuming nutrient-rich foods support retinal function. Vision aids and rehabilitation help those with residual vision loss maintain daily functionality and quality of life.